Antitrust Antitrust

Comment: Juno, Natco, Celgene authorization will set precedent for Australian patent settlements

By Laurel Henning
  • 27 May 2022 04:39
  • 27 May 2022 04:39
While there’ve been numerous authorizations in Australia relating to the supply or distribution of pharmaceutical products, this is the first time the Australian Competition & Consumer Commission, or ACCC, has been asked to look at a patent-settlement agreement.

But the ACCC’s authorization decision and the related review over the last five months

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Laurel Henning

Senior Correspondent

Laurel is a senior correspondent specializing in competition law, data privacy and security, in Australia and New Zealand. Laurel reports from Sydney on criminal-cartel legislation and white-collar crime, as well as competition and consumer lawsuits involving companies including Google, Meta Platforms and Apple. While at MLex Laurel has also reported boardroom disputes and shareholder campaigns agitating for changes to company strategy. Laurel joined MLex in 2013 and reported for five years on European energy and climate policies from Brussels. In that time, Laurel covered the regulation of emissions and technological developments pertaining to the energy sector within the EU, as well as the Paris agreement in 2015. A graduate of the University of Liverpool, Laurel studied English and French before beginning a career in journalism with MLex.

Discover MLex

Stay on top of global regulatory developments

Latest News